Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001119 · ClinicalTrials.gov registry record · NA
Effects on the Immune System of Anti-HIV Drugs in Patients Recently Infected With HIV
A NA study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- NA
- Development phase
- 288
- Enrollment target
- 12
- Study locations
NCT00001119: Completed NA study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00001119 is a NA study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 288 participants, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (35% lower). The trial reports 12 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00001119, a NA study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- NA
- Development phase
- 288 participants
- Enrollment target
- 12
- Study locations
Study Summary
The purpose of this study is to find out whether these powerful combinations of anti-HIV drugs are safe and effective for use in patients in the early stages of HIV infection and to find out how patients' immune systems react to HIV and anti-HIV drugs. Doctors generally treat patients in the early stages of HIV infection with the same anti-HIV drugs taken by patients who have had HIV for a long time. These drugs lower the level of HIV in the blood. However, doctors do not know whether patients who take anti-HIV drugs in the early stages of HIV infection actually live longer or have fewer AIDS-related diseases. This study will help doctors answer these questions. In the main study, doctors will look at how 2 different anti-HIV drug combinations affect the immune system. In the 2 substudies, doctors will look at how the body reacts to the hepatitis B vaccine and the tetanus vaccine. These substudies may help doctors learn how HIV-infected patients respond to new infections.
Conditions Studied
Interventions
- DRUG Ritonavir
- DRUG Indinavir sulfate
- DRUG Lamivudine/Zidovudine
- DRUG Abacavir sulfate
- BIOLOGICAL Tetanus Toxoid Vaccine
Study Locations (12)
Washington
- Seattle HIVNET - Seattle
- Univ of Washington - Seattle
- Fred Hutchinson Cancer Research Ctr - Seattle
New York
- New York Univ Med Ctr - New York
- Bronx-Lebanon Hosp Ctr - The Bronx
California
- San Francisco Dept of Hlth / AIDS Office - San Francisco
Illinois
- Univ of Illinois Chicago / Howard Brown Hlth Ctr - Chicago
Massachusetts
- Fenway Community Health Ctr / HIVNET - Boston
Minnesota
- Univ of Minnesota - Minneapolis
Ohio
- Univ of Cincinnati - Cincinnati
Rhode Island
- Mem Hosp of Rhode Island - Pawtucket
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 288 participants |
| Start Date | 1999-10 |
| Phase | NA |
What the finished NCT00001119 record still lists
NCT00001119 is an interventional study that assigns participants to a tested intervention. The registered 288 participants enrollment target is mid-sized for trials with a published cap, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (35% lower).
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 5 interventions - of which Ritonavir is the first listed.
NCT00001119 lists 12 locations in 9 states (Washington, New York, California).
Frequently Asked Questions
What is clinical trial NCT00001119 about?
NCT00001119 is a clinical study titled "Effects on the Immune System of Anti-HIV Drugs in Patients Recently Infected With HIV". The purpose of this study is to find out whether these powerful combinations of anti-HIV drugs are safe and effective for use in patients in the early stages of HIV infection and to find out how patients' immune systems react to HIV and anti-HIV drugs. Doctors generally treat patients in the early ...
What is the current status of trial NCT00001119?
This trial is currently completed. It is a NA study. The enrollment target is 288 participants. The study started on 1999-10.
What conditions does trial NCT00001119 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00001119?
The interventions under investigation include: Ritonavir (DRUG), Indinavir sulfate (DRUG), Lamivudine/Zidovudine (DRUG), Abacavir sulfate (DRUG), Tetanus Toxoid Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00001119?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00001119 being conducted?
This trial has 12 study locations across California, Illinois, Massachusetts, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00001119's enrollment target sits among peer trials
288 127th of 542 higher than 415 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
RECRUITING · NA
-
Community-based Education, Navigation, and Support Intervention for Military Veterans
RECRUITING · NA
-
WiseApp for Spanish Speakers Living With HIV
RECRUITING · NA
-
Comprehensive HIV and Harm Prevention Via Telehealth
RECRUITING · NA
-
Substance Checking Outreach and Pre-Exposure Prophylaxis (PrEP) Engagement Study
RECRUITING · NA
-
Food as Medicine for HIV and Diabetes
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02098265 · 288 participants · NA
A Closed Loop Neural Activity Triggered Stroke Rehabilitation Device
- NCT03741777 · 288 participants · NA
Comparison of Residual Gastric Volume Between Children Who Drink Different Clear Oral Fluid Volume
- NCT03937635 · 288 participants · Phase 3
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
- NCT04621877 · 288 participants · NA
Lay-Delivered Behavioral Activation in Senior Centers
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia